Literature DB >> 17264369

Investigation of various growth mechanisms of solid tumour growth within the linear-quadratic model for radiotherapy.

H McAneney1, S F C O'Rourke.   

Abstract

The standard linear-quadratic survival model for radiotherapy is used to investigate different schedules of radiation treatment planning to study how these may be affected by different tumour repopulation kinetics between treatments. The laws for tumour cell repopulation include the logistic and Gompertz models and this extends the work of Wheldon et al (1977 Br. J. Radiol. 50 681), which was concerned with the case of exponential re-growth between treatments. Here we also consider the restricted exponential model. This has been successfully used by Panetta and Adam (1995 Math. Comput. Modelling 22 67) in the case of chemotherapy treatment planning. Treatment schedules investigated include standard fractionation of daily treatments, weekday treatments, accelerated fractionation, optimized uniform schedules and variation of the dosage and alpha/beta ratio, where alpha and beta are radiobiological parameters for the tumour tissue concerned. Parameters for these treatment strategies are extracted from the literature on advanced head and neck cancer, prostate cancer, as well as radiosensitive parameters. Standardized treatment protocols are also considered. Calculations based on the present analysis indicate that even with growth laws scaled to mimic initial growth, such that growth mechanisms are comparable, variation in survival fraction to orders of magnitude emerged. Calculations show that the logistic and exponential models yield similar results in tumour eradication. By comparison the Gompertz model calculations indicate that tumours described by this law result in a significantly poorer prognosis for tumour eradication than either the exponential or logistic models. The present study also shows that the faster the tumour growth rate and the higher the repair capacity of the cell line, the greater the variation in outcome of the survival fraction. Gaps in treatment, planned or unplanned, also accentuate the differences of the survival fraction given alternative growth dynamics.

Entities:  

Mesh:

Year:  2007        PMID: 17264369     DOI: 10.1088/0031-9155/52/4/012

Source DB:  PubMed          Journal:  Phys Med Biol        ISSN: 0031-9155            Impact factor:   3.609


  7 in total

Review 1.  Linear quadratic and tumour control probability modelling in external beam radiotherapy.

Authors:  S F C O'Rourke; H McAneney; T Hillen
Journal:  J Math Biol       Date:  2008-09-30       Impact factor: 2.259

Review 2.  Dissecting cancer through mathematics: from the cell to the animal model.

Authors:  Helen M Byrne
Journal:  Nat Rev Cancer       Date:  2010-03       Impact factor: 60.716

3.  Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice.

Authors:  Nelson L Jumbe; Yan Xin; Douglas D Leipold; Lisa Crocker; Debra Dugger; Elaine Mai; Mark X Sliwkowski; Paul J Fielder; Jay Tibbitts
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-04-28       Impact factor: 2.745

4.  A mathematical model for brain tumor response to radiation therapy.

Authors:  R Rockne; E C Alvord; J K Rockhill; K R Swanson
Journal:  J Math Biol       Date:  2008-09-25       Impact factor: 2.259

5.  Second cancers after fractionated radiotherapy: stochastic population dynamics effects.

Authors:  Rainer K Sachs; Igor Shuryak; David Brenner; Hatim Fakir; Lynn Hlatky; Philip Hahnfeldt
Journal:  J Theor Biol       Date:  2007-08-12       Impact factor: 2.691

6.  On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach.

Authors:  Nahor Haddish-Berhane; Dhaval K Shah; Dangshe Ma; Mauricio Leal; Hans-Peter Gerber; Puja Sapra; Hugh A Barton; Alison M Betts
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-08-10       Impact factor: 2.745

7.  Modelling the interplay between hypoxia and proliferation in radiotherapy tumour response.

Authors:  J Jeong; K I Shoghi; J O Deasy
Journal:  Phys Med Biol       Date:  2013-06-21       Impact factor: 3.609

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.